GlassScriptPhysician profile
Matthew N Peters
NPI 1588956304
$9,140.62
in general payments reported to CMS, 2019-2025
37 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $162 · 2021: $937 · 2022: $1,706 · 2023: $3,075 · 2024: $841 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,252 · Travel and Lodging: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,252.39 |
| Travel and Lodging | $1,290.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,641.96 | 2019-2023 | Pascal |
| E.R. Squibb & Sons, L.L.C. | $807.92 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $682.15 | 2019-2025 | |
| Pfizer INC. | $627.65 | 2019-2025 | |
| Amgen INC. | $508.99 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $499.28 | 2022-2025 | Aveir, Assurity, Gallant |
| Janssen Pharmaceuticals, INC | $495.17 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.31 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $443.83 | 2019-2025 | Breztri, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $405.50 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $298.10 | 2023-2025 | General - Crm_crm, Watchman, Watchman Access System |
| Medtronic, INC. | $273.94 | 2022-2025 | Onyx Frontier, Linq II, Micra |
| Amarin Pharma, INC. | $228.81 | 2021-2023 | |
| Scpharmaceuticals INC. | $183.33 | 2023-2025 | |
| Novo Nordisk INC | $170.65 | 2022-2025 | Wegovy, Ozempic |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.